在偏头痛中埃雷努马布的升级 - - 双剂量没有额外的益处 - - 一个回顾经验
Simon Heintz1, Peter Storch2, Philipp Burow1
1Department of Neurology, University Hospital Halle, Martin Luther University Halle- Wittenberg, Wittenberg, Germany.
Acta neurologica Belgica
|July 27, 2024
概括
从70毫克增加到140毫克的Erenumab剂量并没有改善难以治疗的偏头痛患者的结果. 这项研究没有发现较高剂量的头痛减少或反应率的额外益处.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 作为CGRP受体抗体的Erenumab对偏头痛是有效的.
- 关于剂量增加的数据有限,特别是在耐药患者中.
研究的目的:
- 评估在真实世界偏头痛患者中将埃伦乌马布剂量增加到140毫克的疗效.
- 具体评估对70毫克埃伦鲁马布不反应的患者的结局.
主要方法:
- 来自德国三级头痛中心的52名偏头痛患者的回顾性分析.
- 患者接受了70毫克的埃伦乌马布至少3个月,然后升级到140毫克.
- 评估了3个月间的头痛日,急性药物使用和药物过量使用.
主要成果:
- 虽然70毫克的erenumab改善了头痛天,并实现了50%的响应率,但升级到140毫克没有进一步显著的益处.
- 这种缺乏额外的益处在整个研究人群中是一致的,包括慢性和偶发性偏头痛子组.
- 只有5.14%的70毫克不响应者在140毫克剂量时获得了50%的响应.
结论:
- 在难以治疗的偏头痛患者群体中证实了Erenumab的有效性.
- 从70毫克升至140毫克的剂量升级,在这个队列中没有提供额外的临床益处.
相关概念视频
01:20Desensitization and Tachyphylaxis
1.6K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.6K
01:17Drugs for Treatment of Diarrhea-Predominant IBS
156
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
156